Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASBSP:A1SN34 55 Days Payable is 454.26 as of Mar. 2026, which is 43% below its 10-year median of 803.58. GuruFocus rates BSP:A1SN34 with a GF Score™ of 55/100. The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, Ascendis Pharma AS ranks better than 72.08% on this metric.
The historical rank and industry rank for Ascendis Pharma AS's Days Payable or its related term are showing as below:
BSP:A1SN34'
s Days Payable Range Over the Past 10 Years
Min: 323.08 Med: 803.58 Max: 4299
Current: 323.08
During the past 13 years, Ascendis Pharma AS's highest Days Payable was 4299.00. The lowest was 323.08. And the median was 803.58.
BSP:A1SN34's Days Payable is ranked better than 72.08% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs BSP:A1SN34: 323.08
Ascendis Pharma AS's Days Payable
declined
from Mar. 2025 (477.41) to Mar. 2026 (454.26).
It may suggest that Ascendis Pharma ASaccelerated paying its suppliers.
Ascendis Pharma AS Days Payable Related Terms
Ascendis Pharma AS Days Payable Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:A1SN34 vs JAZZ, BBIO, EXEL: Days Payable Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ascendis Pharma AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (BSP:A1SN34) has a Days Payable of 454.26 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ascendis Pharma AS and its competitors. This is 43% below median its historical median of 803.58. Over the past decade, Ascendis Pharma AS's Days Payable has ranged from 323.08 to 4,299.00. According to the industry distribution chart, Ascendis Pharma AS ranks #196 out of 702 companies in the Biotechnology industry, placing it in the top 27.9%.
Is Ascendis Pharma AS's Days Payable too high?
Ascendis Pharma AS's current Days Payable of 454.26 is 43% below median its 10-year median of 803.58. Over the past 10 years, this metric has ranged from a low of 323.08 to a high of 4,299.00. The Biotechnology industry median Days Payable is 113.10. Ascendis Pharma AS's value of 454.26 is 301.6% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #196 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Days Payable compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #196 out of 702 companies for Days Payable. This puts Ascendis Pharma AS in the upper half of its industry. The industry median Days Payable is 113.10. Ascendis Pharma AS's value of 454.26 is 301.6% above this benchmark. Historically, Ascendis Pharma AS's own Days Payable has ranged from 323.08 to 4,299.00 over the past decade. While the company's 10-year median is 803.58 vs. the industry median of 113.10, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Days Payable of 454.26 is 301.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Days Payable is 454.26, which is 43% below median its own 10-year median of 803.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (BSP:A1SN34) has a current Days Payable of 454.26. The current Days Payable is 454.26, which is 43% below median its 10-year median of 803.58 and 301.6% above the Biotechnology industry median of 113.10. Ascendis Pharma AS's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ascendis Pharma AS (BSP:A1SN34), the current Days Payable is 454.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
55GF Score
Get the complete analysis for BSP:A1SN34
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:A1SN34 has been successfully added to your 
